New oncological therapies and the "right" price Authors Enrico Bosone Direttore Corporate Affairs and Market Access, Celgene srl, Milano - Italy DOI: https://doi.org/10.33393/grhta.2015.325
Downloads PDF (Italian) How to Cite Bosone, E. (2015). New oncological therapies and the "right" price. Global and Regional Health Technology Assessment, 2(1), 59–60. https://doi.org/10.33393/grhta.2015.325 More Citation Formats ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver Download Citation Endnote/Zotero/Mendeley (RIS) BibTeX Issue Vol. 2 No. 1 (2015): January-April 2015 Section Correspondence License Copyright (c) 2015 The authors This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Metrics Statistics Abstract views - 589 times PDF (Italian) downloads - 553 times Sign up Browse Sections Health Technology Assessment Health Policies banners150 0.8 2023CiteScore 28th percentile Powered by Completed peer reviews since:November 4, 2020 Most popular articles in the last 30 days Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy 231 Towards a Green Health Technology Assessment: embedding Life Cycle Assessment for sustainable choices 201 Paving the road for a successful EU HTA Reform implementation 200 Assessment and value of drugs: report of the focus groups from the XXII National Conference on Pharmaceuticals 198 Assessing the economic burden of Waldenström’s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL) 197